Patients N=94 | |
Age at 15-year follow-up (years) (mean, SD) | 47.8 (7.8) |
EDSS (median, IQR) | 1.50 (1.0–3.0) |
Number of female patients | 65 (69%) |
Length of follow-up (years) (median, IQR) | 14.29 (12.9–16.9) |
Clinical characteristics | |
Patients with optic neuritis at onset | 78 (83%) |
Patients developed optic neuritis during follow-up | 3 (3%) |
Patients with clinically unilateral optic neuritis | 61 (65%) |
Patients with clinically bilateral optic neuritis* | 20 (21%) |
Patients who did not develop optic neuritis in either eye at follow-up | 13 (14%) |
Subclinical optic neuritis eyes | 10 (5.3%) |
Total optic neuritis eyes at follow-up | 111 (59%) |
Total unaffected eyes at follow-up | 77 (41%) |
Diagnosis at follow-up | |
CIS | 18 (19%) |
RRMS | 63 (67%) |
SPMS | 13 (14%) |
Diagnosis other than MS | 0 (0%) |
Time to CDMS† (months) | 29.4 (7.47–54.47) |
On DMT at follow-up ‡ | 23 (24%) |
Brain MRI | |
T2 lesion volume (median, IQR) | 3.97 mL (0.94–14.22) |
Brain parenchymal fraction (mean, SD) | 0.75 (0.043) |
Grey matter fraction (mean, SD) | 0.46 (0.030) |
White matter fraction (mean, SD) | 0.28 (0.022) |
*Bilateral optic neuritis denotes patients with a history of optic neuritis in both eyes at any point in time (not simultaneous or bilateral sequential).
†Clinically definite multiple sclerosis (CDMS).
‡ Disease modifying therapy (DMT)
CIS, clinically isolated syndrome; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis ; RRMS, relapsing-remitting MS ; SPMS, secondary progressive MS.